
Amy Lightner is a Professor of Surgery in the Department of Surgery at Scripps Clinic in San Diego, CA and Chief Medical Office of Direct Biologics, LLC a biotechnology company in Regenerative Medicine. Dr. Lightner received her B.A. in Human Biology from Stanford University, completed her surgical training in General Surgery at University of California at Los Angeles and post-doctoral work at Stanford University under a California Institute of Regenerative Medicine Training Grant focused on the differentiation pathways of embryonic stem cells. After completing her fellowship at Mayo Clinic, she stayed on as surgical faculty, and was the Medical Director for the Center for Regenerative Medicine at Mayo Clinic. She was then recruited to Cleveland Clinic as Associate Professor to focus on complex inflammatory bowel disease, continue her work in translational science and clinical trials, and start a regenerative medicine program. She founded, and was medical director of the Center for Regenerative Medicine and Surgery at Cleveland Clinic Foundation, and continued her basic science research in stem cell therapy. She is the PI of six active phase II clinical trials using mesenchymal stem cells for inflammatory bowel disease, has received extramural funding from the Helmsley Foundation, Crohn’s and Colitis Foundation, Cure for IBD, Rainin Foundation and American Society of Colon and Rectal Surgery (ASCRS). She is a member of the editorial board of Inflammatory Bowel Diseases, Colorectal Disease, British Journal of Surgery, Crohn’s and Colitis 360, and Diseases of the Colon and Rectum, the surgical co-chair for the European Crohn’s and Colitis Organization annual meeting, the associate chair of the inflammatory bowel disease committee of ASCRS, vice chair of the national clinical practice guidelines committee for ASCRS, and chair of the surgical research committee for ASCRS.
Selected publications from PubMed
Clinical Practice Guideline for the Surgical Management of Ulcerative Colitis.
Lightner AL, Leeds IL, McGee MF, Dawes AJ, Peterson CY, Krane MK, Hedrick TL, Gaertner WB, Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons
Dis Colon Rectum. 2026 Aug 1;69(8):2012-2039 doi: 10.1097/DCR.0000000000004290.
Invited commentary on "Functional outcomes of transanal ileal pouch-anal anastomosis in patients with ulcerative colitis: inverse probability weighting analysis of a single-center cohort".
Lightner AL
J Gastrointest Surg. 2025 Oct;29(10):102196 doi: 10.1016/j.gassur.2025.102196.
Emerging Technologies in Inflammatory Bowel Disease: A Minireview on Future Treatment Modalities.
Folsom MR, Lightner AL
Surg Clin North Am. 2025 Apr;105(2):301-311 doi: 10.1016/j.suc.2024.09.004.
Perianal Fistulizing Crohn's Disease: Outcomes of Surgical Repairs and Current State of Stem Cell-Based Therapies.
Dawes AJ, Lightner AL
Clin Colon Rectal Surg. 2025 Mar;38(2):126-140 doi: 10.1055/s-0044-1786543.
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Preventing Surgical Site Infection.
Shogan BD, Vogel JD, Davis BR, Keller DS, Ayscue JM, Goldstein LE, Feingold DL, Lightner AL, Paquette IM, Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons
Dis Colon Rectum. 2024 Nov 1;67(11):1368-1382 doi: 10.1097/DCR.0000000000003450.

The management of anal fistulas is one of the greatest challenges. The need to preserve continence while permanently eradicating the fistula is the ultimate desired goal. Unfortunately, none of the ever-expanding myriads of treatments is a panacea; high rates of failure and of recurrence are consistently experienced. Regenerative or autologous tissue replacement therapies differ from all other options in encouraging tissue growth rather than destroying, ablating, or excising tissue. This program will demonstrate the role of autologous stem cells and gracilis muscle interposition in the treatment of some of the most challenging fistulas.
With Takeda
Published
Jun 2023

Welcome & Introduction - Dr. Steve Wexner (USA) Rationale and development of Stem cells - Dr. Damian Garcia Olmo, Madrid, Spain Results of stem cell treatment - Dr. Julia Panes, Hospital Clinic, Barcelona, Spain Ongoing scientific trials - Dr. David Schwartz, Vanderbilt University, Nashville, Tennessee Potential future directions and additional indications - Dr. Amy Lightner, Cleveland Clinic Foundation, Ohio Discussion and closing remarks – All faculty moderated by Dr. Steve Wexner (USA)
With Takeda
Published
Oct 2021
Help your network discover Dr. Amy Lightner's clinical expertise.